Talazoparib, initially approved as a monotherapy in BRCA1/2-mutated breast cancer and in combination with enzalutamide for HR-deficient prostate cancer, is currently under Phase II investigation for patients with solid tumors harboring DDR gene mutations, including BARD1 [134]. This evidence concerns the gene BRCA1 and prostate cancer.